A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers.

Trial Profile

A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2013

At a glance

  • Drugs ARRY 382 (Primary)
  • Indications Advanced breast cancer; Bone metastases; Colorectal cancer; Endometrial cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Array BioPharma
  • Most Recent Events

    • 23 Oct 2013 Results presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
    • 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top